Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy

Table 1 Comparison of clinical data of patients, n (%)

Characteristic	Total (n = 101)
Age (year), median (IQR)	63 (54-71)
Sex
Male	54 (53.5)
Female	47 (46.5)
ECOG PS
0	38 (37.6)
1	63 (62.4)
Primary tumor site
Stomach	83 (82.2)
Gastroesophageal junction	18 (17.8)
Disease stage
Locally advanced	14 (13.9)
Metastatic	87 (86.1)
Chemotherapy regimen
Platinum-doublet (SOX/XELOX)	48 (47.5)
Taxane-based	53 (52.5)
BMI (kg/m2), median (IQR)	22.2 (19.6-23.2)
Tumor markers
AFP elevated	6 (5.9)
CEA elevated	51 (50.5)
CA19-9 elevated	51 (50.5)
CA12-5 elevated	12 (11.9)
CA72-4 elevated	62 (61.4)
Molecular markers
PD-L1 positive	80 (79.2)
EBV positive	8 (7.9)
dMMR	3 (3)
Cytokines (binary)
IL-4 high	41 (40.6)
IL-6 high	33 (32.7)
IL-8 high	62 (61.4)
IL-10 high	38 (37.6)
IL-17 high	51 (50.5)
Cytokines (pg/mL), median (IQR)
IL-4	0.32 (0.29-0.35)
IL-6	2.10 (2.05-2.15)
IL-8	14.20 (9.00-19.30)
IL-10	3.20 (2.30-4.40)
IL-17	3.30 (2.85-3.65)

IQR: Interquartile range; ECOG: Eastern Cooperative Oncology Group; PS: Performance status; SOX: Oxaliplatin + tegafur/gimeracil/oteracil; XELOX: Oxaliplatin + capecitabine; BMI: Body mass index; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; PD-L1: Programmed death-ligand 1; EBV: Epstein-Barr virus; dMMR: Deficient mismatch repair; IL: Interleukin.